The enhancement of combination of berberine and metformin in inhibition of DNMT1 gene expression through interplay of SP1 and PDPK1

Fang Zheng a, JingJing Wu a, Qing Tang a, Qian Xiao a, WanYin Wu b, *, Swei Sunny Hann b, *

a Laboratory of Tumor Biology, Guangdong Provincial Hospital of Chinese Medicine, The Second Clinical Medical Collage, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province, China

b Department of Medical Oncology, Guangdong Provincial Hospital of Chinese Medicine, The Second Clinical Medical Collage, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province, China

Received: May 9, 2017; Accepted: July 14, 2017

Abstract

Berberine (BBR), one of active alkaloid found in the rhizome, exhibited anti-cancer properties. We have showed that BBR inhibited growth of non-small cell lung cancer (NSCLC) cells through mitogen-activated protein kinase (MAPK)-mediated increase in forkhead box O3a (FOXO3a). However, the in-depth mechanism underlying the anti-tumor effects still remained to be elucidated. Herein, we further confirmed that BBR not only induced cell cycle arrest, but also reduced migration and invasion of NSCLC cells. Mechanistically, we observed that BBR reduced 3-phosphoinositide-dependent protein kinase-1 (PDPK1) and transcription factor SP1 protein expressions. Exogenously expressed SP1 overcame BBR-inhibited PDPK1 expression. Moreover, BBR inhibited DNA methyltransferase 1 (DNMT1) gene expression and overexpressed DNMT1 resisted BBR-inhibited cell growth. Intriguingly, overexpressed PDPK1 antagonized BBR-inhibited SP1 and DNMT1 expressions. Finally, metformin enhanced the effects of BBR both in vitro and in vivo. Collectively, we observe that BBR inhibits proliferation of NSCLC cells through inhibition of SP1 and PDPK1; this results in a reduction of DNMT1 expression. The interplay of PDPK1 and SP1 contributes to the inhibition of DNMT1 in response to BBR. In addition, there is a synergy of BBR and metformin. This study uncovers a new mechanism of BBR in combination with metformin for NSCLC-associated therapy.

Keywords: Berberine • Metformin • NSCLC • PDPK1 • SP1 • DNMT1

Introduction

Lung cancer is the most common and lethal malignancy worldwide. Among this, the majority of patients are NSCLC and demonstrate with advanced stages [1]. Despite substantial advances in diagnosis and management, the outcomes for this malignancy are still unfavourable. Studies have demonstrated potential benefits using other potential therapeutics in patients with lung cancer [2, 3]. Chinese herbal medicine and its components play an important role in cancer patients in reducing other treatment related complications, and improving quality of life (QOL) including lung malignancy [4, 5]. However, the mechanisms by which these herbal components in associating with the therapeutic efficiency in the treatment of lung cancer still remains to be elucidated.

Chemical compounds derived from plants with wide range of pharmacological and biochemical effects have been used over decades for a number of diseases including cancer. A large growing body of evidence have demonstrated that BBR, an active alkaloid from the rhizome and a number of Chinese herbs, has anticancer effects [6, 7]. BBR has been reported to inhibit cell proliferation and induce apoptosis in multiple cancer types [8–11]. For example, BBR demonstrated the abilities in inhibition of migratory and invasion of prostate cancer cells through regulation of epithelial-to-mesenchymal transition (EMT)-related genes, and this may provide potential therapeutic targets in patients with prostate cancer [12]. Moreover, BBR reduced breast cancer cell growth by generating reactive oxygen species via mitochondrial-related apoptotic pathway [13]. Moreover, BBR blocked doxorubicin (DOX)-induced activation of signal transducer and activator of transcription 3 (STAT3) and enhanced the cytotoxic
activator protein-2 beta (AP-2 β) through activating caspase and inhibiting transcription factors. Melatonin, a known natural antioxidant, showed to enhance the anti-lung cancer effects of natural antioxidant therapies as well [18]. Report suggested that the reciprocal targeting of protein kinases and DNMT1 may be considered as a novel strategy for substantial therapeutic responses in lung cancer as well [32]. Thus, inhibition of DNMT1 could be a promising therapeutic potential for lung cancer. At present, the links between the PDPK1 and DNMT1 have not been well studied.

In this study, we examined potential mechanism by which BBR alone and combining with MET inhibited lung cancer cell proliferation. Our results demonstrate that BBR inhibits growth, migration and invasion of NSCLC cells through inhibition of SP1 and PDPK1; subsequently, this results in the inhibition of DNMT1 gene expression. In addition, there is a potential synergy of BBR combining with MET in this process.

Materials and Methods

Reagents

Monoclonal antibodies against DNMT1 and SP1 were purchased from Cell Signaling Technology Inc. (Beverly, MA, USA). The PDPK1, GAPDH, total Akt and the phosphor-form (Ser473) antibodies were obtained from Abcam (Cambridge, MA, USA). MET was purchased from Enzo (Grand Island, NY, USA), MTT powder was obtained from Roche (Basel, Switzerland). Control (pCMV6-AC or pCMV6-GFP), DNMT1, PDPK1 and Akt overexpression plasmids and PDPK1 promoter constructs were purchased from OriGene Technologies (Rockville, MD, USA). BBR was purchased from Chengdu Must Biotechnology Company (Chengdu, Sichuan, China). Agents were dissolved with DMSO, and freshly diluted to the working concentration with medium before use.

Cell lines and cultures

Human NSCLC cells (A549 and H1975) were obtained from the Chinese Academy of Sciences Cell Bank of Type Culture Collection (Shanghai, China). The cells were cultured at 37°C in a humidified atmosphere containing 5% CO2. The culture medium consisted of RPMI 1640 medium obtained from Life Technologies (GIBCO) supplemented with 10% (v/v) heat-inactivated foetal bovine serum (GIBCO, Grand Island, NY, USA), 100 μg/ml streptomycin and 100 U/ml penicillin.

Cell viability assay

We used 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) method to determine cell viability as described previously [33].
NSCLC cells (6 × 10^4 cells/96-microwell plate) were treated with increasing concentrations of BBR for up to 72 hrs. Afterwards, 10 μl MTT solution (5 g/l) was added and incubated at 37°C for an additional 4 hrs. Finally, after removing the supernatant, 150 μl solvent dimethyl sulfoxide (DMSO) was added and oscillated for 10 mins. Afterwards, absorbance at 570 nm was determined through the use of ELISA reader (BioTek, Epoch, VT, USA). Cell viability (%) was calculated as follows: (absorbance of test sample/absorbance of control) ×100%.

**Cell proliferation assay**

NSCLC cells were cultivated in 96-micro-well plates at a density of 6 × 10^3 cells/well and treated with increasing concentrations of BBR for 48 hrs. For the last 16 hrs, cells were added with BrdU labelling solution (final concentration: 10 μM BrdU). Subsequently, the incorporation rate of BrdU was determined using a commercial enzyme-linked immunosorbent assay (ELISA) kit (Roche, Indianapolis, IN, USA). A colormetric reaction with tetramethylbenzidine (TMB) as a substrate gave rise to a reaction product measured at 370 nm using a scanning multi-well spectrophotometer (BioTek).

**Cell cycle analysis**

NSCLC cells (3 × 10^5 cells/well) were cultured in 6-well plates and treated with increased doses of BBR for 24 hrs. Then, the cells were harvested and resuspended in 70% pre-cold ethanol at −20°C, followed by incubating with 0.1% sodium citrate containing propidium iodide (PI) 0.05 mg and 50 μg RNase for 30 min. Finally, the cell cycle analysis was detected by flow cytometry (FC500, Beckman Coulter, Brea, CA, USA), and the proportion of cells within the G0/G1, S and G2/M phases of the cell cycle were analysed using the Multi-Cycle AV DNA Analysis software (Phoenix Flow Systems, Inc., San Diego, CA, USA).

**Wound-healing assay**

Wound-healing assay was used to examine NSCLC cells migration ability. The cells were grown to 100% confluence in six-well plates and incubated with starvation medium overnight. Cell monolayers were wounded with a sterile 200 μl pipette tip and washed to remove detached cells. Cells were treated with indicated doses of BBR for 24 hrs; afterwards, the medium was replaced with PBS, and the wound gap was observed and photographed using an Olympus microscope fitted with digital camera (Olympus, Tokyo, Japan).

**Cell invasion assays**

The invasion assays were processed by using of the Transwell plate (Corning, Corelle NY, USA) with 10 mm diameter and 8 μM pore size polycarbonate membrane. Before the experiment, the Matrigel (BD, Franklin Lakes, NJ, USA) was diluted to eightfold, which was injected into the upper chamber of transwell system. The lower chamber was added into 500 μl of cell culture medium with 20% FBS. Afterwards, cells were diluted to 0.5 × 10^6/ml and pre-treated with BBR (50 μM), and add 200 μl A549 cells suspension into the Matrigel. Following 24-hrs incubation, cells remained in upper membrane were wiped, while cells migrated or invaded were fixed with 4% paraformaldehyde, stained with 0.1% crystal violet, and counted under a microscope (Olympus Corporation).

**Quantitative real-time PCR (qRT-PCR)**

A quantitative real-time PCR assay was developed for the detection of the expression of DNMT1. GAPDH was used as an endogenous control. The primers used in this study were designed as follows: DNMT1: forward 5'-GTGAGGACATGAGCTTCA -3' and reverse 5'-TGTCTGCTTTGACAGTGTCG-3'; GAPDH (used as an internal control): forward 5'-CTCCTCTGTGGAGACATGAGCTG-3' and reverse 5'-CCCAATACGACCAAATCGGT-3'. Total RNA was extracted using the TRIzol solution, and the first-strand cDNA was synthesized from total RNA (1 μg) by reverse transcription using PrimeScript™RT Reagent Kit (Takara Bio Inc., Kyoto Japan) according to the manufacturer’s instructions. Quantitative real-time PCR was performed in a 20 μl mixture containing 2 μl of the cDNA preparation using SYBRremix En Taq™II (Tli RNaseH Plus) Kit (Takara Bio Inc.) on an ABI 7500 Real-Time PCR System (Applied Biosystems, Grand Island, NY, USA). The PCR conditions were as follows: 30 sec. at 95°C, followed by 40 cycles of 5 sec. at 95°C and 34 sec. at 60°C. Each sample was tested in triplicate. Relative expression of DNMT1 was calculated as ΔΔCt, measured by subtracting the Ct of the GAPDH.

**Western blot analysis**

The detailed method was based on previous report [33]. Whole cell lysates containing same amount of protein were solubilized in 3× SDS-sample buffer and separated on 10% SDS polyacrylamide gels. PVDF Membranes (Millipore, Billerica, MA, USA) were incubated with antibodies against DNMT1, SP1, PDPK1 and GAPDH and 24 hrs incubation, cells remained in upper membrane were wiped, while cells migrated or invaded were fixed with 4% paraformaldehyde, stained with 0.1% crystal violet, and counted under a microscope (Olympus Corporation).

**Transient transfection assays**

The detailed procedure was reported previously [33]. NSCLC cells (5 × 10^5 cells/well) were seeded in 6-well dishes and grown to 70–80% confluence. For each well, 2.5 μg pcDNA 3.1 or SP1 plasmid DNA, kindly provided by Dr. Thomas E. Eling (NIEHS, Research Triangle Park, NC, USA) [34], and 1.5 μg pCMV6-AC/GFP or DNMT1, Akt expression vectors or 2.5 μg PDPK1 plasmid were transfected into the cells using the lipofectamine 3000 reagent according to the manufacturer’s instructions for up to 24 hrs, followed by treating with BBR for an additional 24 hrs. In separated experiment, cell were transfected with pEZX-PG04-DNMT1 promoter construct linked Gaussia luciferase (GLuc) gene and secreted alkaline phosphatase (SEAP) internal control obtained from GeneCopoeia, Inc. Secrete-Pair Dual Luminescence Assay Kit (GeneCopoeia, Inc Rockville, MD, USA) was used to determine luciferase activities, which was normalized with SEAP within each sample.
**Tumour xenografts and bioluminescent imaging**

Animal study was approved and carried out in accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals in cancer research of Use Committee of Guangdong Provincial Hospital of Chinese Medicine. A total of 24 eight-week-old female nude mice obtained from Guangdong Provincial Research Center for Laboratory Animal Medicine (Foshan, Guangdong, China) were maintained at the Animal Center of Guangdong Provincial Hospital of Chinese Medicine. A549 cells carrying luciferase report gene (A549-Luc, obtained from the Guangzhou Land Technology Co., Guangzhou, China) in 0.2 ml medium (phenol red free RPMI 1640 with 2% FBS) were injected subcutaneously into the nude mice. Xenografts were allowed to grow for over 1 week when the tumour diameters reached 3 mm × 4 mm made with callipers. Mice were randomly divided into following groups: vehicle (DMSO), BBR (10 mg/kg, ip, QOD)[8], MET, (250 mg/kg, ig, QD) [35] and the combination groups for up to 3 weeks. For bioluminescence imaging (BLI) procedure, the mice were anaesthetized by inhalation of 2% isoflurane at the end of experiment. Each set of mice were injected with 150 mg/kg D-luciferin (Caliper Life Sciences, Hopkinton, MA, USA) in approximately 200 μl. Imaging and quantification of signals (photons/sec.) were obtained using the IVIS-200 Imaging System (Xenogen Corporation, Berkeley, CA, USA). Tumour volume measurements were calculated using the formula for an oblong sphere: volume = (width2 × length). The bodyweights of mice were measured twice a week. All mice were killed on day 21 by cervical dislocation with minimum suffering in accordance with the Guide for the Care and Use of Laboratory Animals. The corresponding extracted xenografts were processed for detecting the DNMT1, SP1, PDPK1 proteins by Western blot.

**Statistical analysis**

The majority of experiments were repeated a minimum of three times. All data are expressed as mean ± S.D. Differences between groups were assessed by one-way or two-way ANOVA, and significance of difference between particular treatment groups was analysed using Dunnett’s multiple comparison tests by GraphPad Prism software version 5.0. (Graph Pad software, Inc. San Diego, CA, USA, www.graphpad.com). Asterisks showed in the figures indicate significant differences of experimental groups in comparison with the corresponding control condition. P-values <0.05 were considered statistically significant.

**Results**

**BBR inhibited growth, migration, invasion, and induced cell cycle arrest in lung cancer cells**

We previously showed that BBR inhibited growth of human lung cancer A549 cells [15]. In the current study, we further substantiated the effect of inhibition affected by BBR. As expected, we observed that BBR significantly inhibited growth of an additional NSCLC cell H1975 (Fig. 1A) using both MTT and colorimetric BrdU ELISA methods. Next, the experiments of cell cycle phase distribution treated with increased doses of BBR for 24 hrs showed that BBR significantly increased the proportion of cells at G2/M phase and reduced the proportion of cells at S phases (Fig. 1B), suggesting that BBR induced cell cycle arrested in G2/M phase in H1975 cells. Moreover, we studied in vitro invasive properties of lung cancer cells in responding to BBR using matrigel-coated transwell experiments. The results indicated that BBR inhibited invasion of H1975 and A549 cells (Fig. 1C). Furthermore, BBR significantly reduced wound gap closure compared to the untreated control cells as determined by wound healing assays, indicating reduction of migration by BBR in H1975 and A549 cells (Fig. 1D). The results above confirmed the multiple anti-lung cancer effects of BBR in this process.

**BBR decreased protein expression of PDPK1 and SP1**

We next explored the molecular mechanism by which BBR inhibited cell growth. First, in order to identify the relevant targets of BBR in this process, we began to investigate the role of transcription factor SP1 and one key kinase PDPK1, both of which have been involved in the tumour growth and progression [16, 17, 36]. Our results showed that BBR reduced protein expressions of SP1 and PDPK1 in a dose-dependent manner in A549 and H1975 cells (Fig. 2A and B). Next, we further examined the potential interaction between the SP1 and PDPK1 signalling. As shown in Figure 2C, exogenously expressed SP1 reversed the BBR-reduced PDPK1 protein expression. This result indicated that SP1 regulated PDPK1 expression in this process.

**BBR inhibited DNMT1 mRNA, protein and promoter activity**

To dissect the mechanism and gain insight into the biological significance of the interaction between SP1 and PDPK1, we further elucidated the potential downstream effectors. In this study, we have deciphered the role of DNMT1, which is the target of SP1 [37] and recently have been reported to be associated with PDPK1 signalling [38]. We showed that BBR inhibited the protein, mRNA and promoter activity of DNMT1 in H1975 and A549 cells as determined by Western Blot, qTR-PCR and Secrete-Pair Dual Luminescence Assay Kit, respectively (Fig. 3A–C).

**Overexpression of DNMT1 resisted cell growth inhibition affected by BBR**

In order to further interrogate the importance of DNMT1 expression and the ability of DNMT1 to influence the expression of SP1, PDPK1, and regulate cell growth, the exogenously expressed DNMT1 gene were transfected into the cells. We observed that while overexpressed DNMT1 had little effect on influencing the BBR-reduced SP1 and PDPK1 protein levels, it significantly overcame BBR-inhibited growth of NSCLC cells (Fig. 4A and B). On the contrary, exogenously
expressed PDPK1 appeared to resist BBR-inhibited DNMT1 and SP1 protein expressions (Fig. 4C). It also antagonized BBR-reduced DNMT1 promoter activity (Fig. 4D). The findings above suggested that the mutual regulation of SP1 and PDPK1 could reduce DNMT1 expression and that inhibition of DNMT1 at translational and transcriptional levels by BBR was involved in the inhibition of NSCLC cell growth.

The synergistic effects of BBR and MET

Metformin, a known AMPK activator and drug for the treatment of type 2 diabetes, has been shown to have anti-tumour effects [39]. Herein, we also asked whether combination of MET and BBR could have synergistic effects. We found that combing with MET showed to further enhance the effects of BBR on not only cell growth (Fig. 5A),...
but also the protein levels of SP1, PDPK1 and DNMT1 (Fig. 5B–D). This implied a potential synergy in this process. Because of the crucial role of PDPK1 downstream PI3-K/Akt pathway in cancer growth and progression [21, 40] and the reported links of the Akt in regulation of SP1 and DNMT1 expressions in several cancer types in other studies [33, 38, 41], we then assessed the role of Akt signalling in this process. Our results showed that BBR and MET alone reduced the phosphorylation of Akt, and that more robust inhibition was observed in combination with MET and BBR treatment group in A549 and H1975 cells (Fig. 5E). Note that the total Akt had no changes by these treatments. Moreover, exogenously expressed Akt into the cells resisted the effects of combination of MET and BBR on reduction of SP1 and DNMT1 protein expressions in A549 and H1975 cells (Fig. 5F). Together, these findings above indicated that combination

Fig. 2 BBR decreased protein expression of PDPK1 and SP1. (A–B) A549 and H1975 cells were exposed to increased concentrations of BBR for 24 hrs, followed by measuring PDPK1 and SP1 proteins by Western blot. (C) A549 and H1975 cells were transfected with the control or expression constructs of SP1 for 24 hrs before exposing the cells to BBR for an additional 24 hrs. Afterwards, SP1 and PDPK1 protein expressions were determined using Western blot. Figures are representative cropped gels/blots that have been run under the same experimental conditions. Values are given as the mean ± S.D. from three independent experiments. *indicates a significant difference from the control group (P < 0.05).
of MET and BBR reduced phosphorylation of Akt, and that inactivation of Akt involved in the combination of MET and BBR-reduced expressions of SP1 and DNMT1 in this process.

**In vivo anti-tumour efficacy of BBR in mice**

To further clarify the findings in vitro, we also assessed the effect of BBR on lung cancer growth in vivo. Mice bearing xenografted tumour was treated every other day for the control, BBR alone (10 mg/kg) [8] via intraperitoneal injection, MET, (250 mg/kg) by gavages [35] and the combination of BBR and MET [42] for up to 21 days. We found that the BBR, MET alone, and the combination of BBR and MET-treated mice groups showed significant delayed tumour growth without any severe adverse responses as compared to that in the control group assessed by the Xenogen IVIS200 System (Fig. 6A). The difference in the levels of luciferase expression correlated with the tumour area. In addition, we observed significant reduction of the tumour weight and volume in the BBR, MET alone as compared to that in the control group. The combination group showed a greater suppression (Fig. 6B–D). By Western blot, fresh tumours harvested from the aforementioned experiment showed that BBR efficiently decreased SP1, PDPK1 and DNMT1 protein expressions in vivo as compared to that in the control one and that the combination of BBR and MET had even greater effects (Fig. 6E).

**Discussion**

In this study, we investigated the consequence of human lung cancer cells to the treatment of BBR in the presence or absence of MET, confirming the anti-lung cancer property of BBR in this process. Our current study showed that BBR inhibited growth of NSCLC cells through inhibition of SP1 and PDPK1; subsequently, this resulted in the reduction of DNMT1 gene expression. In addition, there is a potential synergy of BBR and MET. To our knowledge, this is for the first time to show that MET sensitized human lung cancer cell growth inhibition in response to BBR or vice versa.

We further explored the molecular mechanism underlying the anti-lung cancer efficacy of BBR, studies observed signalling pathways and potential targets that were involved in the anti-cancer responses of BBR in different cancer types [8, 43]. We previously
Fig. 4 Overexpression of DNMT1 resisted cell growth inhibition affected by BBR. (A) A549 and H1975 cells were transfected with the control (pCMV6) or expression constructs of DNMT1 for 24 hrs before exposing the cells to BBR (50 μM) for an additional 24 hrs. Afterwards, PDPK1, SP1 and DNMT1 proteins were determined by Western blot. Figures are representative cropped gels/blots that have been run under the same experimental conditions. (B) A549 and H1975 cells were transfected with the control or expression constructs of DNMT1 for 24 hrs before exposing the cells to BBR (50 μM) for an additional 48 hrs. Afterwards, the cell viability was determined using the MTT assay as described in the Materials and Methods section. Insert on the upper panel represented the protein levels of DNMT1 as determined using Western blot. GAPDH was used as internal control. (C) A549 and H1975 cells were transfected with the control (pCMV6) or expression constructs of PDPK1 for 24 hrs before exposing the cells to BBR (50 μM) for an additional 24 hrs. Afterwards, PDPK1, SP1 and DNMT1 proteins were determined by Western blot. GAPDH was used as control. Figures are representative cropped gels/blots that have been run under the same experimental conditions. (D) A549 and H1975 cells were transfected with the control (pCMV6) or expression constructs of PDPK1, and wild-type human DNMT1 promoter reporter construct ligated to luciferase reporter gene and internal control secreted alkaline phosphatase for 24 hrs, followed by treating with BBR for an additional 24 hrs. Afterwards, the promoter activities were determined using the Secrete-Pair Dual Luminescence Assay Kit as described in the Materials and Methods section. Insert on the upper panel represented the protein levels of PDPK1 as determined using Western blot. Values in bar graphs were given as the mean ± S.D. from three independent experiments. * indicates significant difference as compared to the untreated control group (P < 0.05). ** indicates significant difference from the BBR treated alone (P < 0.05).
showed that BBR inhibited proliferation and induced apoptosis of NSCLC cells through p38 MAPK-mediated increase in p53 and FOXO3a expressions [15]. Herein, the current study indicated that reduction in transcription factor SP1 and one key member of AGC kinase family, PDPK1, was also involved in the inhibitory effect of BBR on NSCLC cell growth. As universal transcription factor, SP1 has been well considered to be involved in the growth, progression and metastasis of several cancer types [44]. Moreover, the regulation of SP1 by BBR was also found in other studies; death-domain-associated protein (DAXX) regulated many cellular signalling pathways for
cell growth and apoptosis, and through disrupting the association of SP1 binding to the DAXX gene promoter, BBR inhibited the DAXX promoter activity, thereby inducing human neuroblastoma cell apoptosis [45]. Another report observed that BBR suppressed hepatocellular carcinoma cell growth by upregulating miRNA-22-3p and downregulating the expression of SP1, thereby reducing the expressions of its
downstream targets, CCND1, (cyclin D1), a oncogenic cell-cycle-related protein and BCL2, an apoptosis-related protein [46]. Hwang-gyunhaedok-tang (HRT), one of a traditional medicine, which contained BBR, showed to inhibit the adipocyte differentiation by reducing adipocyte-specific transcription factors, including PPARγ, CCAAT/enhancer binding protein beta (C/EBPβ), in 3T3-L1 pre-adipocytes through downregulation of multiple pathways including extracellular MAPK 1 (MEK1)/ERK1/2 and PDPK1/Akt [47]. Intriguingly, we observed the novel links of SP1 and PDPK1 in the current study and suggested that there appeared a mutual regulation between SP1 and PDPK1, which resulted in the inhibition of DNMT1 expression and NSCLC growth affected by BBR. This novel interaction between SP1 and PDPK1 has not been shown so far. Thus, the mechanism underlying this interaction and subsequent outcomes required to be further determined. Nevertheless, our results have demonstrated important roles of these two tumour promoters in the growth and progression of lung cancer.

Furthermore, our observation has suggested a critical role of DNMT1 in mediating the effect of BBR on inhibiting growth of NSCLC cells. DNMT1 not only is a key maintenance methyltransferase [25] but also involves in tumour growth and progression [23, 26, 27, 32, 48]. Several lines of evidence have demonstrated that increased expression of DNMT1 exists in several cancer types including lung and that targeting DNMT1 suppresses cancer cell growth [27, 29, 49, 50]. Our results suggested that DNMT1 functioned as one of downstream effectors of SP1 and PDPK1, and that reduction in DNMT1 was involved in the BBR-inhibited NSCLC cell growth. Studies have unveiled an important role for DNMT1 in modulating other gene expression through interacting with some transcription factors in other study [51]. The modulation of SP1 and PDPK1 expression influenced the DNMT1 expression and functions have been reported in other studies as well. The SP family has been shown to bind to common cis-elements in the promoter regions of various genes including DNMT1, thereby regulating DNMT1 expression [37, 52], SP1 modulated the expression of DNMT1 gene through mechanisms such as protein abundance, post-translational modifications or interaction with other transcription factors in human acute myeloid leukaemia cells [52]. One study demonstrated that p53, by forming a complex with SP1 on the DNMT1 gene promoter, reversely controlled DNMT1 expression; thus, deregulation of DNMT1 was associated with gain of transcriptional activation of SP1. This resulted in epigenetic alteration of multiple tumour suppressor genes and ultimately led to lung tumorigenesis [53]. We previously showed that β-elemene, a compound derived from Rhizoma zedoariae, inhibited NSCLC cell growth via extracellular signal-regulated kinase1/2 (ERK1/2)- and AMPKα-mediated inhibition of SP1, and this resulted in reduction in DNMT1 protein [33]. In studying the potential mechanisms underlying the hypermethylation of tumour suppressor genes in helicobacter pylori (HP)-induced gastric carcinoma, one study observed that interaction of PDPK1 and Akt caused to increase in Akt phosphorylation, thereby activating NF-κB bound to DNMT1 promoter and increasing its expression in gastric carcinoma cells [38]. However, less information showed the direct connection of PDPK1 and DNMT1, we believed that this is a first report, which provided the novel insight into the connection between PDPK1 and DNMT1 affected by BBR, and also highlighted the tumour promoter function of PDPK1 and DNMT1 that were involved in the anti-tumour effect of BBR in this process. Nevertheless, the in-depth mechanism of this interplay in mediating the anti-tumour effect of BBR required to be further elucidated.

Moreover, our results unveiled at least an additive, or perhaps a synergistic effect of combination of BBR and MET in the inhibition of SP1, PDPK1 and DNMT1 expressions, and lung cancer cell growth, implying the potential new role and molecular mechanism in combination with BBR and MET in controlling NSCLC cell growth. MET, as a potential anticancer agent, has been shown to inhibit growth and induce apoptosis through AMPK-dependent and AMPK-independent signalling pathways in NSCLC cells [35, 54, 55]. Substantial efficacy of MET and BBR in combining has been reported in other studies as well [56]. One study found that BBR and MET inhibited mitogenic signalling in pancreatic ductal adenocarcinoma cells through AMPK-dependent and AMPK-independent pathways [42]. In the current study, we reasoned that MET sensitized the effects of BBR on controlling NSCLC cell growth through enhancing the inhibition of PDPK1, SP1 and DNMT1 expressions, or vice versa. However, whether the effect of MET was depending on AMPK-mediated pathway required to be determined. Moreover, because of the crucial role of PDPK1 downstream PI3-K/Akt pathway in cancer growth and progression [21, 40] and the reported links of this pathway in the regulation of SP1 and DNMT1 expressions in other studies [33, 38, 41], we also assessed the role of Akt signalling in this study. Our results suggested that inactivation of Akt by BBR combining with MET was involved in the reduced expressions of SP1 and DNMT1. This was in line with other reports [57–59] highlighting the key role of this kinase signalling in this process. Of note, the findings obtained from BBR and MET combination treatment suggested at least an additive effect existed in our system, the statistical significance specifically for the true synergy and the clinical significance of this combination therapy need to be determined. Nevertheless, all the results might provide some solid information for guiding the combinational treatment using natural anticancer compounds and other agents in enhancing efficiency for lung cancer treatment.

More importantly, our in vivo data were consistent with the findings from that in vitro, confirming the enhanced effect of BBR in the presence of MET on inhibition of lung cancer [8, 60, 61], and regulation of SP1, PDPK1 and DNMT1 expressions. The doses of BBR or/ and MET used were based on other studies [8, 35, 42]. Given the fact that the information of actual doses of these in animal blood remained to be determined, we think that further experiments are required to obtain this. In addition, more studies are also needed to further determine the role of DNMT1 in this process using cells stable transfected with shRNAs or/and exogenously DNMT1 expression vectors in nude mouse model. In addition, whether BBR has potential in prolonging the survival and inhibiting metastasis in lung xenografted tumours required to be elucidated.

Collectively, our results show that BBR inhibits growth of NSCLC cells through inhibition of SP1 and PDPK1; subsequently, this results in the reduction in DNMT1 gene expression. The reciprocal interplay of PDPK1 and SP1 contributes to the inhibition
of DNMT1 gene expression in response to the effects of BBR. In addition, there is a potential synergy of BBR and MET (Fig. 6F). This study reveals a novel mechanism in response to BBR in combination with MET and suggests a new strategy for NSCLC-associated adjuvant therapy.

Acknowledgements

This work was supported in part by the grants from the National Nature Scientific Foundation of China (81272614, 81403216), the Science and Technology Program of Guangzhou (201607010385), the Discipline of Integrated Chinese and Western Medicine in Guangzhou University of Chinese Medicine (A1-AF-D01816121513), the Special Science and Technology Join fund from Guangdong Provincial Department of Science and Technology-Guangdong Academy of Traditional Chinese Medicine (2012A032500011, 2014A020221024) and The Specific Research Fund for TCM Science and Technology of Guangdong Provincial Department of Science and Technology-Guangdong Academy of Chinese Medicine (YK2013B2N13, YN2015MS19).

Author contributions

S.S.H. is fully responsible for the study designing, experiment adjustment, drafting and finalizing the manuscript. F.Z. performed most of the experiments involved. J.J.W. carried out part of transfection assays and some protein measurement by Western blot and statistical analysis. Q.X. conducted part of densitometry, statistical analysis and participated in coordination manuscript. Q.X. executed part of the MTT assays, some overexpression experiments and statistical analysis. W.Y.W. coordinated and provided important suggestions including some reagents, and critical reading the manuscript. All authors read and approved the final manuscript.

Conflicts of interest

The authors have declared that no competing interests exist.

References

1. Torre LA, Siegel RL, Jemal A. Lung Cancer Statistics. Adv Exp Med Biol. 2016; 893: 1–19.
2. Dudani S, Leighl NB, Ho C, et al. Approach to the non-operative management of patients with stage II non-small cell lung cancer (NSCLC): a survey of Canadian medical and radiation oncologists. Lung Cancer. 2016; 94: 74–80.
3. Hussain S. Nanomedicine for Treatment of Lung Cancer. Adv Exp Med Biol. 2016; 890: 137–47.
4. Han Y, Wang H, Xu W, et al. Chinese herbal medicine as maintenance therapy for improving the quality of life for advanced non-small cell lung cancer patients. Complement Ther Med. 2016; 24: 81–9.
5. Wu X, Chung VC, Lu P, et al. Chinese herbal medicine for improving quality of life among non-small cell lung cancer patients: overview of systematic reviews and network meta-analysis. Medicine (Baltimore). 2016; 95: e2410.
6. Tillhon M, Guzman Ortiz LM, Lombardi P, et al. Berberine: new perspectives for old remedies. Biochem Pharmacol. 2012; 84: 1260–7.
7. Zeu K, Li Z, Zhang Y, et al. Advances in the study of berberine and its derivatives: a focus on anti-inflammatory and anti-tumor effects in the digestive system. Acta Pharmacol Sin. 2017; 38: 157–67.
8. Lu JJ, Fu L, Tang Z, et al. Melatonin inhibits Akt/p38alpha/hTERT, NF-kappaB/COX-2 and Akt/ERK and activates caspase/Cyto C signaling to enhance the anti-tumor activity of berberine in lung cancer cells. Oncotarget. 2016; 7: 2985–3001.
9. Ma W, Zhu M, Zhang D, et al. Berberine inhibits the proliferation and migration of breast cancer ZR-75-30 cells by targeting Ephrin-B2. Phytomedicine. 2017; 25: 45–51.
10. Zhuo Y, Chen Q, Chen B, et al. Berberine promotes antiproliferative effects of epirubicin in T42 bladder cancer cells by enhancing apoptosis and cell cycle arrest. Int J Clin Pharmacol Ther. 2017; 52: 32–40.
11. Wang C, Wang H, Zhang Y, et al. Berberine inhibits the proliferation of human nasopharyngeal carcinoma cells via an Epstein-Barr virus nuclear antigen 1-dependent mechanism. Oncol Rep. 2017; 37: 2109–2120.
12. Liu CH, Tang WC, Shia P, et al. Berberine inhibits the metastatic ability of prostate cancer cells by suppressing epithelial-to-mesenchymal transition (EMT)-associated genes with predictive and prognostic relevance. Int J Med Sci. 2015; 12: 63–71.
13. Xie J, Xu Y, Huang X, et al. Berberine-induced apoptosis in human breast cancer cells is mediated by reactive oxygen species generation and mitochondrial-related apoptotic pathway. Tumour Biol. 2015; 36: 1279–88.
14. Zhu T, Li LL, Xiao GF, et al. Berberine increases doxorubicin sensitivity by suppressing STAT3 in lung cancer. Am J Chin Med. 2015; 43: 1487–502.
15. Zheng F, Tang Q, Wu J, et al. p38 alpha MAPK-mediated induction and interaction of FOX03a and p53 contribute to the inhibited-growth and induced-apoptosis of human lung adenocarcinoma cells by berberine. J Exp Clin Cancer Res. 2014; 33: 36.
16. Raimondi C, Falasca M. Targeting PDK1 in cancer. Curr Med Chem. 2011; 18: 2763–9.
17. Gagliardi PA, di Biasio L, Primo L. PDK1: a signaling hub for cell migration and tumor invasion. Biochim Biophys Acta. 2015; 1856: 178–88.
18. Raimondi C, Callieva V, Ferro R, et al. A Small molecule inhibitor of PDK1/PKGammal interaction blocks breast and melanoma cancer cell invasion. Sci Rep. 2016; 6: 26142.
19. Du J, Yang M, Chen S, et al. PDK1 promotes tumor growth and metastasis in a spontaneous breast cancer model. Oncogene. 2016; 35: 3314–23.
20. Han L, Zhang G, Zhang N, et al. Prognostic potential of microRNA-138 and its target mRNA PDK1 in sera for patients with non-small cell lung cancer. Med Oncol. 2014; 31: 129.
21. Di Biasio L, Gagliardi PA, Pulifatto A, et al. Serine/threonine kinase 3-phosphoinositide-dependent protein kinase-1 (PDK1) as a Key regulator of cell migration and cancer dissemination. Cancers (Basel). 2017; 9: 25.
22. Hann SS, Tang Q, Zheng F, et al. Repression of phosphoinositide-dependent protein kinase 1 expression by ciglitazone via Egr-1 represents a new approach for inhibition of lung cancer cell growth. Mol Cancer. 2014; 13: 149.
23. Zhang W, Xu J, DNA methyltransferases and their roles in tumorigenesis. Biomark Res. 2017; 5: 1.
24. Jones PA. DNA methylation and cancer. Oncogene. 2002; 21: 5358–60.
25. McGraw S, Zhang JX, Farag M, et al. Transient DNMT1 suppression reveals hidden heritable marks in the genome. Nucleic Acids Res. 2015; 43: 1485–97.
27. Wu J, Lin H, Hsu TC, et al. IL-6 enriched lung cancer stem-like cell population by inhibition of cell cycle regulators via DNMT1 upregulation. Int J Cancer. 2015; 136: 547–59.

28. Cheng P, Wang YF, Li G, et al. Interplay between menin and DNMT1 reversibly regulates pancreatic cancer cell growth downstream of the Hedgehog signaling pathway. Cancer Lett. 2016; 370: 136–44.

29. Chen X, Guo H, Li F, et al. Physcion 8-O-beta-glucopyranoside suppresses the metastasis of breast cancer in vitro and in vivo by modulating DNMT1. Pharmacol Rep. 2017; 69: 36–44.

30. Wu J, Zhao S, Tang Q, et al. Inactivation of SAPK/JNK mediated the inhibition and reciprocal interaction of DNA methyltransferase 1 and EZH2 by uracil acid in human lung cancer cells. J Exp Clin Cancer Res. 2015; 34: 99.

31. Han X, Zhen S, Ye Z, et al. A feedback loop between miR-30a/c-5p and DNMT1 mediates cisplatin resistance in ovarian cancer cells. Cell Physiol Biochem. 2017; 41: 973–86.

32. Huang C, Liu H, Song XL, et al. Effect of evodiamine and berberine on the interaction between DNMTs and target microRNAs during malignant transformation of the colon by TGF-beta1. Oncol Rep. 2017; 37: 1637–45.

33. Yan F, Shen N, Pang J, et al. The DNA methyltransferase DNMT1 and Tyrosine-Protein Kinase Kit cooperatively promote resistance to 5-Aza-2’-deoxycytidine (Decitabine) and Midostaurin (PKC412) in lung cancer cells. J Biol Chem. 2015; 290: 18480–94.

34. Zhao S, Wu J, Zheng F, et al. beta- elemene inhibited expression of DNA methyltransferase 1 through activation of ERK1/2 and AMPKalpha signalling pathways in human lung cancer cells: the role of Sp1. J Cell Mol Med. 2015; 19: 630–41.

35. Kambe A, Iuchi G, Moon Y, et al. Regulation of EP4 expression via the Sp-1 transcription factor: inhibition of expression by anti-cancer agents. Biochim Biophys Acta. 2008; 1783: 1211–9.

36. Storozhuk Y, Hopmans SN, Sanli T, et al. Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK. Br J Cancer. 2013; 108: 2021–32.

37. Hsu TC, Wang MC, Chen SY, et al. Sp1 expression regulates lung tumor progression. Oncogene. 2012; 31: 3973–88.

38. Kishikawa S, Murata T, Kimura H, et al. Regulation of transcription of the Dnmt1 gene by Sp1 and Sp3 zinc finger proteins. Eur J Biochem. 2002; 269: 2961–70.

39. Zhang BG, Hu L, Zhang MD, et al. Helicobacter pylori CagA induces tumor suppressor gene hypermethylation by upregulating DNMT1 via AKT-NFkappaB pathway in gastric cancer development. Oncotarget. 2016; 7: 9786–800.

40. Sarbasov DD, Guertin DA, Ali SM, et al. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 2005; 307: 1098–101.

41. Wang ZQ, Cai Q, Hu L, et al. Long noncoding RNA UCA1 induced by Sp1 promotes cell proliferation via recruiting EZH2 and activating AKT pathway in gastric cancer. Cell Death Dis. 2017; 8; e2839.

42. Ming M, Sinnett-Smith J, Wang J, et al. Dose-Dependent AMPK-Dependent and Independent Mechanisms of Berberine and Metformin Inhibition of mTORC1, ERK, DNA Synthesis and Proliferation in Pancreatic Cancer Cells. PLoS ONE. 2014; 9: e114573.

43. Jabbarzadeh Kaboli P, Rahmat A, Ismail P, et al. Metformin exerts antiproliferative and anti-metastatic effects against cholangiocarcinoma cells by targeting STAT3 and NF-kB. Anticancer Res. 2017; 37: 115–23.

44. Hu Y, Young AJ, Ehl EA, et al. Metformin and berberine prevent olate stimulated weight gain in rats. PLoS ONE. 2014; 9: e93310.

45. Agarwal S, Amin KS, Jagadeesh S, et al. Mahanine restores RASSF1A expression by down-regulating DNMT1 and DNMT3B in prostate cancer cells. Mol Cancer. 2013; 12: 99.

46. Chen Y, Tang Q, Wu J, et al. Inactivation of PI3-K/Akt and reduction of Sp1 and p65 expression increase the effect of salomazine on suppressing EP4 expression in human lung cancer cells. J Exp Clin Cancer Res. 2013; 34: 154.

47. Chen X, Cheung KC, Cheung YC, et al. Berberine suppresses Id1 expression and inhibits the growth and development of lung metastases in hepatocellular carcinoma. Biochim Biophys Acta. 2015; 1852: 541–51.

48. Kiyatly SK, Meera SM, Kiyatly N, et al. Berberine-induced growth inhibition and apoptosis of non-small cell human lung cancer cells in vitro and tumor xenograft growth in vivo. Mol Carcinog. 2009; 48: 24–37.